Prostate Scotland statement on SMC decision on enzalutamide for high-risk non metastatic castration resistant prostate cancer
“We are disappointed that it has been decided not to make enzalutamide available as an option for the treatment of...
“We are disappointed that it has been decided not to make enzalutamide available as an option for the treatment of...
